Showing 291-300 of 9109 results for "".
- Coming Soon? The first FDA-approved Topical Prescription Product for Molluscumhttps://practicaldermatology.com/news/coming-soon-the-first-fda-approved-topical-prescription-product-for-molluscum/2461485/Ligand Pharmaceuticals Inc.’s partner Novan submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking marketing approval for berdazimer gel, 10.3% (SB206) for the topical treatment of molluscum contagiosum. Assuming the filing is accepted by the FDA and given a …
- Castle's DecisionDx-SCC Provides Clarity in Assessing Risk SCC Spread in Challenging Staging Situationshttps://practicaldermatology.com/news/castles-decisiondx-scc-provides-clarity-in-assessing-risk-scc-spread-in-challenging-staging-situations/2461436/Castle Biosciences, Inc.’s DecisionDx-SCC test provides objective, independent and significant risk-stratification for cutaneous squamous cell carcinoma (cSCC) tumors with uncertainty in differentiation status. The data were shared in an oral presentation given at the American Society of Dermatop…
- European Commission Approves LEO Pharma’s Adtralza (tralokinumab) for the Treatment of Moderate-to-Severe AD in Adolescentshttps://practicaldermatology.com/news/european-commission-approves-leo-pharmas-adtralza-tralokinumab-for-the-treatment-of-moderate-to-severe-ad-in-adolescents/2461394/The European Commission (EC)e xtended the marketing authorization for LEO Pharma’s Adtralz (tralokinumab) to include adolescents aged 12 to 17 with moderate-to-severe atopic dermatitis (AD) who are candidates for systemic therapy. “Safety is a priority when selecting a treatment option for adoles…
- CHMP Recommends Adtralza (tralokinumab) for the Treatment of Adolescents With Moderate-to-Severe ADhttps://practicaldermatology.com/news/chmp-recommends-adtralza-tralokinumab-for-the-treatment-of-adolescents-with-moderate-to-severe-ad/2461351/The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) is recommending extending the approval of LEO Pharma’s Adtralza (tralokinumab) to include adolescents aged 12 to 17 with moderate-to-severe atopic dermatitis (AD) who are candidates for systemic therapy…
- Positive Dupixent Phase 3 Data in Children Aged 6 Months to 5 Years with Moderate-to-severe ADhttps://practicaldermatology.com/news/positive-dupixent-phase-3-data-in-children-aged-6-months-to-5-years-with-moderate-to-severe-ad/2461349/Dupixent significantly improved skin clearance, and reduced itch and overall disease severity in children as young as 6 months old, according to a new Phase 3 trial in the Lancet. These data were the basis for the U.S. Food and Drug Administration (FDA) approval of Dupixent in June 2022 and for a …
- Researchers ID Sensor Underlying Mechanical Itchhttps://practicaldermatology.com/news/researchers-id-sensor-underlying-mechanical-itch/2461248/Scientists at Scripps Research have identified a protein in sensory nerves that works as a key detector of the “mechanical” itch stimulus of crawling insects, wool fibers, or other irritating objects that touch the skin. The discovery, published June 22, 2022, in Nature, is the first identificatio…
- Dermatologists Rule for Cosmetic Procedures and Skin Care Decisionshttps://practicaldermatology.com/news/dermatologists-rule-for-cosmetic-procedures-and-skin-care-decisions/2461241/Dermatologists rank as the number one influencer among 16 factors that impact consumers’ decisions to have a cosmetic procedure, according to the 2021 American Society for Dermatologic Surgery (ASDS) Consumer Survey on Cosmetic Dermatologic Procedures. When selecting a practitioner, the specialty …
- The Skin Cancer Foundation Raises $625,000 For Skin Cancer Education Programs at Annual Galahttps://practicaldermatology.com/news/the-skin-cancer-foundation-raises-625000-for-skin-cancer-education-programs-at-annual-gala/2461200/The Skin Cancer Foundation Champions for Change Gala raised $625,000 in support of the organization’s educational campaigns, community programs and research initiatives. More than 300 guests attended the event, including Skin Cancer Foundation donors, industry and physician allies, celebrity supp…
- TOOsonix System ONE-M BCC Clinical Trial Updatehttps://practicaldermatology.com/news/toosonix-system-one-m-bcc-clinical-trial-update/2461162/The first basal cell carcinoma (BCC) patients have been treated with TOOsonix A/S’s System ONE-M device. The TOOsonix high-intensity focused ultrasound (HIFU) delivers highly accurate doses of energy to focal points in a chosen depth. It operates at 20 MHz to create a thermal focal zones in the e…
- Mount Sinai Health System Launches Alopecia Areata Center of Excellencehttps://practicaldermatology.com/news/mount-sinai-health-system-launches-alopecia-areata-center-of-excellence/2461115/In an effort to deliver outstanding comprehensive care and to employ revolutionary approaches to novel therapeutics around the skin condition alopecia areata, the Mount Sinai Health System has launched the Alopecia Areata Center of Excellence. Under the leadership of Director Emma Guttman-Yassky, M…